Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)

被引：0
|
作者：
Thaci, D. [1 ]
Deleuran, M. [2 ]
Bissonnette, R. [3 ]
Bouaziz, J. D. [4 ]
Sun, X. [5 ]
Patel, N. [6 ]
Shumel, B. [5 ]
机构：
[1] Univ Lubeck, Lubeck, Germany
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Innovaderm Res, Montreal, PQ, Canada
[4] Hop St Louis, Paris, France
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Bridgewater, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P01
引用
收藏
页码：E94 / E94
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Open-Label Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE)
    Thaci, Diamant
    Deleuran, Mette
    Bissonnette, Robert
    Bouaziz, Jean-David
    Sun, Xian
    Shumel, Brad
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 25 - 26
  • [2] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Roh, Joo Young
    Park, Chun Wook
    Kim, Kyu Han
    Lee, Joo Hee
    Sun, Xian
    Rossi, Ana B.
    Shumel, Brad
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53
  • [3] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Herranz, Pedro
    de la Cueva, Pablo
    Rodriguez Marco, Ainara
    Worrell, Richard
    Shumel, Brad
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
  • [4] Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)
    Blauvelt, Andrew
    Guttman-Yassky, Emma
    Paller, Amy S.
    Simpson, Eric L.
    Browning, John
    Chen, Zhen
    Delevry, Dimittri
    Mahajan, Puneet
    O'Malley, John T.
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB97 - AB97
  • [5] Efficacy and safety of dupilumab for up to 1 year in a phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)
    Blauvelt, A.
    Guttman-Yassky, E.
    Paller, A. S.
    Thaci, D.
    Simpson, E. L.
    Browning, J.
    Bastian, M.
    Chen, Z.
    Delevry, D.
    O'Malley, J. T.
    Bansal, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 9 - 9
  • [6] Dupilumab treatment for up to 3 years demonstrates sustained efficacy and favorable safety in adult patients with moderate-to-severe atopic dermatitis: results From LIBERTY AD Adult OLE
    Blauvelt, A.
    Hussain, I.
    Zhu, X.
    Beazley, B.
    Patel, N.
    Worrell, R.
    Ruddy, M.
    Graham, N. M. H.
    Shumel, B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 28 - 29
  • [7] Efficacy and safety of dupilumab for up to 1 year in a phase III open-label extension trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled moderate-to-severe atopic dermatitis
    Blauvelt, A.
    Guttman-Yassky, E.
    Simpson, E. L.
    Browning, J.
    Chen, Z.
    Bansal, A.
    O'Malley, J. T.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E116 - E116
  • [8] Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE
    Blauvelt, Andrew
    Hussain, Iftikhar
    Beazley, Bethany A.
    Patel, Naimish
    Ruddy, Marcella
    Staudinger, Heribert
    Graham, Neil M. H.
    Shumel, Brad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB175 - AB175
  • [9] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    Blauvelt, Andrew
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Hide, Michihiro
    Sher, Lawrence
    Hussain, Iftikhar
    Chen, Zhen
    Khokhar, Faisal A.
    Beazley, Bethany
    Ruddy, Marcella
    Patel, Naimish
    Graham, Neil M. H.
    Ardeleanu, Marius
    Shumel, Brad
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 567 - 577
  • [10] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Diamant Thaçi
    Mette Deleuran
    Andrew Blauvelt
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Michihiro Hide
    Lawrence Sher
    Iftikhar Hussain
    Zhen Chen
    Faisal A. Khokhar
    Bethany Beazley
    Marcella Ruddy
    Naimish Patel
    Neil M. H. Graham
    Marius Ardeleanu
    Brad Shumel
    American Journal of Clinical Dermatology, 2020, 21 : 567 - 577
12345